Phase I study of high-dose bi-weekly gemcitabine at a constant rate infusion (CRI) without growth factor support in advanced solid tumors, including prior standard gemcitabine treated patients

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 23; no. 16_suppl; p. 2067
Main Authors Bellmunt, J., Trigo, J. M., Garcia-Ribas, I., Roca, J. M., Galtes, S., Perez-Romero, A., de la Cruz, J. J., Tabernero, J. M., Alba, E., Baselga, J.
Format Journal Article
LanguageEnglish
Published 01.06.2005
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2005.23.16_suppl.2067